NexCAR19 in India: Indications, Evidence, Risks and Access Costs
An independent, sourced review of India's first approved indigenous CAR-T therapy: what it is approved to treat, what clinical studies have shown, what its risks are, and where its use ends.
NexCAR19 is a single CD19-directed CAR-T product with defined indications and a defined regulatory status. Its relevance depends on the exact B-cell cancer subtype, prior treatments, the approved indication, access to an authorised centre, and total cost. It should not be evaluated as a general solution for blood cancers or as a substitute for every other CAR-T therapy.
NexCAR19 (talicabtagene autoleucel; previously referred to as actalycabtagene autoleucel in the original prescribing information) is an autologous, CD19-directed CAR-T cell therapy developed in India by ImmunoACT, with development linked to IIT Bombay and Tata Memorial Centre. It received CDSCO approval in October 2023 and was publicly launched in April 2024.
The manufacturer's prescribing information lists its use in patients aged 15 years and older with relapsed or refractory B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL). It is not FDA-approved, and its Indian approval does not establish approval or availability in other countries.
Published cost estimates exist, but a current, itemised written quotation from an authorised treatment centre is required before any travel or payment decision.
1. What NexCAR19 Is — and Is Not
NexCAR19 is a CD19-directed chimeric antigen receptor T-cell therapy developed by ImmunoACT, a spin-off from IIT Bombay, with development links to Tata Memorial Centre. It was India's first approved indigenous CAR-T cell therapy and represents an important development in domestic cell-therapy manufacturing and access. It is not India's only CAR-T product, and it does not represent every CAR-T option available internationally.
What it is:
- A CD19-directed autologous CAR-T cell therapy
- Listed in the manufacturer's prescribing information for patients aged 15 years and older with relapsed or refractory B-cell lymphoma or B-ALL
- Manufactured in India and available through ImmunoACT-authorised treatment centres
- Supported by a phase 1/2 clinical study and a 2026 multicentre real-world analysis
2. Limits of Use — What the Approved Indication Does Not Cover
To avoid repetition, the limits of use are collected in the table below. They are drawn from the manufacturer's prescribing information and the published clinical evidence. This table does not replace the treating team's assessment.
| Domain | Status | Note |
|---|---|---|
| Solid tumours | Not approved | No indication for liver, lung, pancreatic, breast, or colorectal cancer. |
| Multiple myeloma | Not approved | NexCAR19 targets CD19; multiple myeloma is typically approached with BCMA-directed therapies, a different product class. |
| Primary CNS lymphoma | Not recommended | Per the current prescribing information. |
| Active CNS involvement by malignancy | Not indicated | Per the current prescribing information. |
| Prior CNS involvement that was effectively treated | Not automatically excluded | Eligibility assessment remains the treating team's responsibility. |
| Approval in the United States | Not FDA-approved | Indian approval is not US approval and does not replace US regulatory or insurance requirements. |
| Guaranteed access or immediate treatment | Not guaranteed | Regulatory approval does not guarantee case acceptance, a manufacturing slot, or rapid access. |
3. What Do Clinical Studies Show?
Evidence for NexCAR19 includes an open-label, multicentre phase 1/2 study and a later multicentre real-world analysis in India. These studies provide evidence of clinical activity in selected patients with relapsed or refractory B-cell malignancies. They do not establish that every eligible patient will respond, or that NexCAR19 is superior to other CAR-T products.
Phase 1/2 Clinical Study
A multicentre, open-label phase 1/2 study published in The Lancet Haematology in April 2025 evaluated talicabtagene autoleucel in patients with relapsed or refractory B-cell malignancies. A total of 64 patients were enrolled, 57 received the product, and 51 were efficacy-evaluable. The overall response rate was 73% (37 of 51 patients; 95% CI 59–83%).
The study was not a randomised comparison against another CAR-T product, so its results should be interpreted as evidence of activity in the population studied, not as proof of superiority. Two treatment-related deaths were reported, highlighting that CAR-T treatment can involve serious and potentially life-threatening complications.
Reference: Jain H et al. Lancet Haematology. 2025;12(4):e282–e293. DOI: 10.1016/S2352-3026(24)00377-6.
Real-World Evidence Published in 2026
A retrospective multicentre study published in Blood Cancer Journal in July 2026 evaluated 250 patients with relapsed or refractory B-cell malignancies who underwent leukapheresis across 56 Indian treatment centres. Of these, 226 received talicabtagene autoleucel and were included in the reported safety and efficacy analyses.
| Outcome | B-ALL | B-NHL |
|---|---|---|
| Patients who underwent leukapheresis | 105 | 145 |
| Patients infused | 98 | 128 |
| Overall response at day 28 | 88% | 75% |
| Overall response at day 90 | 75% | 59% |
| 12-month progression-free survival | 55% | 47% |
| 12-month overall survival | 64% | 63% |
Median follow-up was approximately 14 months for B-ALL and 13 months for B-NHL. Of 250 patients who underwent leukapheresis, 226 were infused; 18 died before infusion and 6 had product manufacturing issues. This shows that starting the process is not the same as receiving CAR-T.
The results should also not be read as "one infusion without any further treatment": some patients received maintenance therapy or subsequent treatments after CAR-T, at their physicians' discretion. Disease burden and response status before treatment varied between patients; in the B-ALL group, about 40% of patients were MRD-negative and about 35% had morphological disease with at least 5% blasts. Average results therefore cannot be transferred directly to a person with a different disease state.
These results are encouraging, but important limitations remain:
- The study was retrospective and did not include a randomised control group.
- The results apply to the patients who were selected and treated in the participating centres.
- Some patients who underwent leukapheresis did not reach infusion.
- Follow-up is still relatively limited for assessing long-term remission and late effects.
- The study does not establish superiority over other approved CAR-T products.
The study also reported a median of 29 days from leukapheresis to infusion (range 16–102 days).
Reference: Karulkar A et al. Blood Cancer Journal. 2026;16:177. DOI: 10.1038/s41408-026-01569-w.
4. Safety: Risks Patients Must Understand
NexCAR19 is a specialised cellular therapy that requires trained clinical teams, close monitoring, and access to emergency supportive care. It can cause serious and potentially life-threatening adverse events. A lower reported treatment price does not remove the medical risks associated with CAR-T therapy.
Key Adverse Events in the 2026 Real-World Study
| Event | B-ALL (98 patients) | B-NHL (128 patients) |
|---|---|---|
| Grade 3–4 CRS | 6% | 6% |
| Grade 3–4 ICANS | 4% | 3% |
| Grade 3–4 cytopenia in the first month | 76% | 77% |
| IEC-HS (all grades) | 23% | 18% |
Note: IEC-HS in this table is recorded as "all grades" and should not be equated with the CRS/ICANS grading.
Important Risks to Understand
- Cytokine Release Syndrome (CRS): an inflammatory reaction that can occur after CAR-T cells become activated, with symptoms including fever, low blood pressure, rapid heartbeat, chills, and breathing difficulties. Severe cases can require intensive care and medicines such as tocilizumab or corticosteroids. The original prescribing information reported CRS in 68% of treated patients, with grade 3 or higher CRS in about 3 of 57 patients (approximately 5%).
- Neurological Toxicities (ICANS): confusion, difficulty speaking, changes in attention, seizures, or other neurological symptoms. No ICANS cases were reported in the original small clinical safety dataset, but the 2026 real-world study reported grade 3–4 ICANS in some patients. The absence of events in an earlier study should not be interpreted as proof that this risk does not exist.
- Low blood cell counts and infection: CAR-T treatment and the chemotherapy given before infusion can cause significant reductions in blood cells. Patients may develop neutropenia, anaemia, thrombocytopenia, or serious infections, and some require blood-product support, infection treatment, or additional hospital care.
- Other complications: hypogammaglobulinaemia, immune-effector cell-associated haemophagocytic syndrome (IEC-HS), infusion reactions, and prolonged immune-system impairment.
- Secondary malignancy: the current prescribing information includes a warning regarding secondary malignancies. Class-wide CAR-T warnings do not mean the risk has been quantified equally for every product; discuss long-term follow-up with the centre.
When to Contact the Treatment Team Immediately
If fever, difficulty breathing, confusion, or difficulty speaking appears after treatment, contact the treatment team immediately and follow the emergency plan they provided. Do not take medicines or adjust doses on your own.
What the Treatment Centre Must Be Able to Provide
- Experience administering the specific CAR-T product
- Staff trained to recognise and manage CRS and ICANS
- Access to intensive care when required
- Required emergency medicines and supportive-care facilities
- A defined monitoring and discharge protocol
- A clear emergency contact and follow-up plan
Patients should obtain the product-specific safety information and discuss individual risks with their treating haematologist. The figures above describe study populations; they are not an estimate of an individual patient's personal risk.
5. NexCAR19 Cost in India: What Is Publicly Known
NexCAR19 has been described in public reporting as substantially less expensive than commercially available CAR-T products in the United States. However, there is no single price that should be assumed for every patient or treatment centre.
A 2026 publication reports an estimate of approximately US$30,000–50,000, without presenting it as a current quotation or a uniform total cost for international patients. These figures come from different sources and may cover different services; they should not be presented as a fixed manufacturer price or a guaranteed package.
Costs That Must Be Clarified
| Cost component | What the patient should verify |
|---|---|
| CAR-T product and infusion | Whether the quoted price includes the manufactured cell product and infusion |
| Initial assessment | Specialist consultation, laboratory tests, imaging, and eligibility assessment |
| Leukapheresis | Whether cell collection is included |
| Bridging and lymphodepleting treatment | Whether medicines and associated inpatient care are included |
| Hospitalisation | Expected admission period and additional inpatient charges |
| ICU and complication management | Whether emergency care, ICU admission, and medicines are billed separately |
| Follow-up | Required monitoring, consultations, and tests after infusion |
| Travel and accommodation | Costs for the patient and accompanying person |
Before Relying on a Price
Ask the treatment centre for a current written estimate that identifies: the exact hospital and treating team, whether the patient is being assessed for commercial treatment or a clinical trial, what is included and excluded, the expected admission and monitoring period, the financial responsibility if the patient is found ineligible after arriving in India, and the likely additional costs if complications occur.
A low advertised price is not enough to compare treatment options. The relevant figure is the total expected cost of the complete care pathway, including the possibility of additional hospital care.
6. Treatment Timeline and Travel Planning
NexCAR19 treatment involves more than a single infusion. International patients should understand the full process before arranging travel. The manufacturer provides patient guidance on the stages of treatment; patients should consult it directly and obtain a written timeline from the centre.
| Stage | What happens |
|---|---|
| Initial assessment | The treating team reviews diagnosis, previous treatment, current health, and eligibility |
| Leukapheresis | The patient's T-cells are collected in a separate procedure before manufacturing |
| Cell manufacturing | The collected cells are modified and prepared for infusion; the centre and manufacturer determine the expected duration |
| Bridging treatment, if needed | The treating physician may use additional treatment while the CAR-T product is being prepared |
| Conditioning chemotherapy | A short course of chemotherapy is given before infusion |
| CAR-T infusion | The manufactured cells are administered intravenously |
| Hospital monitoring | The patient is monitored for CRS, neurological toxicity, cytopenias, infections, and other complications |
| Follow-up | Ongoing assessment is required after discharge |
A 2026 real-world study reported a median of 29 days from leukapheresis to infusion, with a range of 16–102 days. The centre recommends planning sufficient time near the treatment centre after infusion, including accommodation with a caregiver during the monitoring period.
Total duration varies with clinical condition, manufacturing, bridging treatment, hospital scheduling, complications, and the treating team's instructions. A specific duration should not be assumed for every case; a written timeline should be obtained from the centre before travel.
7. Authorised Treatment Centres and Access
NexCAR19 is not available at every hospital in India. The manufacturer identifies authorised treatment centres through its official centre-finder service. The existence of a hospital partnership does not, by itself, confirm that the hospital is currently accepting new NexCAR19 patients or has an available treatment slot.
Before making travel arrangements, verify the following directly with the manufacturer and the proposed treating centre:
- Is the hospital currently listed as an authorised NexCAR19 treatment centre?
- Is the centre currently administering NexCAR19, rather than only participating in other oncology services?
- Does the centre accept international patients?
- Is the relevant haematology team experienced in treating the patient's specific B-cell malignancy?
- Is there an available leukapheresis and manufacturing slot?
- What is the expected timeline from assessment to infusion?
- What facilities are available for CRS, ICANS, infection, and other complications?
- What is included in the written treatment estimate?
- What follow-up and emergency support will be available after discharge?
The manufacturer provides an official treatment-centre finder: ImmunoACT — Authorised Treatment Centres. Please verify the link before relying on it.
CancerCareE does not rank hospitals or determine clinical suitability. The treating centre must confirm its current authorisation, availability, and ability to assess the individual case.
8. How to Compare NexCAR19 with Other CAR-T Access Pathways
NexCAR19 should not be compared with an entire country's cancer-care system. It is one CD19-directed CAR-T product with defined indications and a defined regulatory status. When comparing treatment pathways, the following questions are more useful than country-level rankings.
| Comparison factor | India: NexCAR19 | Other CAR-T pathways |
|---|---|---|
| Target | CD19 | Depends on the product: CD19, BCMA, or another target |
| Indications | Specific relapsed/refractory B-cell malignancies | Product-specific; must be checked individually |
| Regulatory status | CDSCO-approved in India | Check the relevant regulator and country |
| International approval | Not FDA-approved | Approval differs by product and jurisdiction |
| Clinical evidence | Phase 1/2 study and 2026 real-world multicentre data | Varies by product, indication, and duration of follow-up |
| Access | Through ImmunoACT-authorised treatment centres | Depends on the product, hospital, eligibility, and country |
| Cost | Published estimates exist, but a written centre quotation is required | Product and total-care costs vary considerably |
| Follow-up | Requires a defined post-infusion monitoring plan | Must be confirmed with the treating centre and local physician |
A clinical trial in another country is not automatically a better option, and an approved product is not automatically suitable for every patient. The comparison must be made at the level of the specific therapy and the patient's clinical circumstances. Single-arm real-world data do not, by themselves, establish superiority in efficacy or safety.
9. Limits of Use and What the Treatment Does Not Guarantee
In addition to the indication limits summarised in the table above, NexCAR19 does not guarantee:
- Guaranteed access: regulatory approval does not guarantee that an individual patient will qualify, that a centre will accept the case, or that a manufacturing slot will be available.
- Immediate treatment: the 2026 real-world study reported a median of 29 days from leukapheresis to infusion, with substantial variation. This does not include every step of an international patient's journey.
- Long-term certainty: the available clinical and real-world data are encouraging, but longer follow-up is needed to understand the durability of responses and late effects.
- A replacement for every CAR-T therapy: NexCAR19 is one product and is neither the only nor automatically the best option for every patient.
NexCAR19 may be worth discussing with a specialist for selected patients with relapsed or refractory B-cell malignancies. Whether it is appropriate must be determined by the treating haematology team.
10. Questions to Ask Before Considering Travel
Before making an international treatment decision, patients and families should obtain clear answers from the treating centre.
Diagnosis and eligibility
- Does my exact lymphoma subtype or B-ALL diagnosis fall within the approved indication?
- Is the disease relapsed or refractory under the centre's criteria?
- Is the patient's age within the applicable product indication?
- Are there any CNS-related limitations relevant to this case?
- What additional tests are required before a final eligibility decision?
Treatment availability
- Is the proposed hospital currently an authorised NexCAR19 treatment centre?
- Does it accept international patients?
- Is a leukapheresis slot available?
- What is the expected time from cell collection to infusion?
- What happens if manufacturing is unsuccessful or the patient's condition changes before infusion?
Safety and hospital support
- What is the centre's protocol for CRS and ICANS?
- Is intensive care available if required?
- Which emergency medicines and supportive-care services are available?
- How long is hospital monitoring usually expected?
- How long must the patient and caregiver remain near the centre after infusion?
Financial planning
- Does the written estimate include leukapheresis, manufacturing, conditioning chemotherapy, infusion, and hospitalisation?
- Are ICU care and treatment of complications included?
- What happens financially if the patient does not proceed to infusion?
- What additional costs may arise after discharge?
Follow-up after returning home
- What tests and follow-up visits will be required?
- What clinical information will be provided to the patient's local physician?
- Who should be contacted if complications arise after returning home?
- Can the treating centre coordinate with the patient's local haematologist?
Do not make travel or payment commitments until the treating centre has clarified eligibility, availability, costs, and the post-treatment monitoring plan.
Sources and References
- ImmunoACT — NexCAR19 Prescribing Information. Original prescribing information, version dated 27 October 2023. Includes approved use, warnings, clinical-trial data, and safety information. immunoact.com — Package Insert (PDF)
- Jain H et al. Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study. Lancet Haematology. 2025;12(4):e282–e293. DOI: 10.1016/S2352-3026(24)00377-6. PMID: 40090352.
- Karulkar A et al. Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies: multicenter real-world evidence on delivery, efficacy and safety. Blood Cancer Journal. 2026;16:177. DOI: 10.1038/s41408-026-01569-w. PMID: 42463637.
- National Cancer Institute (NCI). India's First Homegrown CAR T-Cell Therapy Has Roots in NCI Collaboration. 7 February 2024. cancer.gov
- ImmunoACT — NexCAR19 for Healthcare Professionals. immunoact.com/nexcar19-hcp
- ImmunoACT — Authorised Treatment Centres. Official treatment-centre locator. immunoact.com/hospital_list
- U.S. Food and Drug Administration (FDA). Approved Cellular and Gene Therapy Products. fda.gov
- Biotechnology Industry Research Assistance Council (BIRAC). Varnimcabtagene autoleucel (Qartemi) product information. birac.nic.in
- Central Drugs Standard Control Organisation (CDSCO), India. Regulatory information and approved new drug records. cdsco.gov.in
Editorial note: the 2026 real-world study was funded with internal resources and support from ImmunoACT, and several authors report affiliations with the company. This does not invalidate the findings, but it matters when assessing the independence of the evidence and the need for external verification. The study is also a retrospective multicentre analysis, not an independent randomised comparison.
Related CancerCareE Resources
CAR-T Therapy Overview
Understand CAR-T targets, treatment processes, clinical evidence, and important risks.
FDA-Approved CAR-T Indications
Details of the approved indications for CD19-directed CAR-T therapies.
CAR-T Research in China
Investigational CAR-T approaches, trial status, and regulatory differences.
Published CAR-T Cost Comparison
How to compare published prices, hospital quotations, and the total cost of care.
Patient Guide
Practical guidance for patients and caregivers considering treatment abroad.
For Referring Physicians
Information resources for clinicians evaluating referral options.
These resources cover different treatment approaches and should not be interpreted as interchangeable treatment recommendations.
Frequently Asked Questions About NexCAR19
Is NexCAR19 approved in India?
Yes. NexCAR19 received CDSCO approval in October 2023 and was publicly launched in April 2024. It was India's first approved indigenous CAR-T cell therapy.
What cancers is NexCAR19 approved to treat?
The manufacturer's prescribing information lists relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukemia (B-ALL) in patients aged 15 years and older. The exact cancer subtype and other eligibility conditions must be confirmed by the treating haematology team.
Is NexCAR19 suitable for solid tumours?
No. NexCAR19 is a CD19-directed CAR-T product for specific B-cell malignancies. It is not an approved treatment for solid tumours such as liver, lung, breast, pancreatic, or colorectal cancer.
Is NexCAR19 approved by the US FDA?
No. NexCAR19 is approved by India's CDSCO. It is not listed as an FDA-approved cellular therapy product in the United States. Indian regulatory approval does not automatically apply in other countries.
How much does NexCAR19 cost for international patients?
A 2026 publication reported an estimate of approximately US$30,000–50,000. This is a published estimate, not a guaranteed price or a universal international-patient tariff. Patients should request a current, itemised written estimate directly from an authorised treatment centre.
How long does NexCAR19 treatment take?
Timelines vary by case and centre. A 2026 real-world study reported a median of 29 days from leukapheresis to infusion, with a range of 16–102 days. Additional time is required for assessment, preparation, hospital monitoring, and follow-up. A written timeline should be obtained from the centre before travel.
What are the main risks of NexCAR19?
Important risks include cytokine release syndrome (CRS), neurological toxicity (ICANS), low blood cell counts, infections, immune-system complications, and a secondary-malignancy warning in the current prescribing information. Some patients may require intensive care. Treatment must take place at an appropriately equipped authorised centre.
Can international patients receive NexCAR19 in India?
International patients should confirm acceptance directly with an authorised treatment centre and the manufacturer. Regulatory approval does not guarantee that a particular centre will accept an international patient, that a treatment slot will be available, or that the patient will meet clinical eligibility criteria.
Researching NexCAR19 or Other CAR-T Options in India?
CancerCareE provides independent information about CAR-T products, regulatory status, clinical evidence, treatment access, and published cost information.
CancerCareE does not determine medical eligibility, recommend a treatment, or guarantee hospital acceptance. Please do not send medical records to CancerCareE; if a treatment centre requires medical documents, submit them directly through that centre's own secure process.
Access to CancerCareE's general information is free.